Eli Lilly's (LLY) Olumiant (baricitinib) recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areata

• The primary endpoint of this study was a SALT score ≤20 at Week 36

Eli Lilly's recommendation by the CHMP for expanded use of Olumiant in treating adolescents with severe alopecia areata is a positive development that could broaden its market potential in Europe. This approval aligns with ongoing efforts to diversify their portfolio in the pharmaceuticals sector, potentially leading to increased revenue streams. As sentiment shifts towards biopharmaceuticals, this news may bolster investor confidence in LLY shares, impacting both the equities and broader market indices.